Compare Marsh & McLennan Companies, Inc. (MRSH) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Tenet Healthcare Corporation — how do they compare? Marsh & McLennan Companies, Inc. trades at $180.04 (market cap $87.77B), while Tenet Healthcare Corporation trades at $196.03 (market cap $16.74B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 5.2× Tenet Healthcare Corporation's market cap, and Marsh & McLennan Companies, Inc. pays a 2.17% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| MRSH | THC | |
|---|---|---|
Market Cap | $87.77B | $16.74B |
Sector | Financials | Health |
52-Week High | $211.21 | $244.80 |
52-Week Low | $157.32 | $148.38 |
Enterprise Value | $108.61B | $26.99B |
Dividend Yield | 2.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $181.59, down 0.32% on the day, with a bullish technical signal from moving averages and support at $180. The company reported strong Q2 2026 earnings, beating estimates with $2.96 EPS versus $2.88 expected, driven by 6% revenue growth to $7.4 billion. Fundamentals show robust profitability with a 14.26% net margin and 27.42% ROE, while valuation ratios like P/E of 22.77 and P/S of 3.26 reflect premium pricing. Recent news highlights a 10% dividend increase to $0.99 per share, payable in August 2026.
The outlook for MRSH is positive, supported by consistent earnings beats and strategic AI investments, but risks include rising operating expenses and softer insurance pricing. Analysts maintain a consensus price target of $203.75, implying 12% upside, with 11 buy ratings outweighing 1 sell. Investors should monitor expense management and organic growth sustainability amid competitive pressures.
Tenet Healthcare (THC) trades at $194.38, down 0.27% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten EPS estimates for three consecutive quarters, with a Q2 2026 report due July 24. Valuation metrics appear attractive with a P/E of 10.11 and P/S of 0.79. Revenue and net income are projected to grow in 2026, supported by expansion in outpatient care.
The outlook is positive given analyst consensus with 81% buy ratings and a $234.63 price target, implying 21% upside. Risks include potential pressure from lower patient days and high debt levels. Earnings growth and ambulatory care performance remain key catalysts for near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
